LLY

Eli Lilly and Company [LLY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LLY Stock Summary

Top 10 Correlated Stocks

LLY


In the News

08:47 16 Apr 2024 LLY

3 Magnificent Stocks That Could Double or More by 2030

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

10:05 16 Apr 2024 LLY

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

09:27 16 Apr 2024 LLY

EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts

The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.

09:11 16 Apr 2024 LLY

Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say

Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts said Friday.

07:11 16 Apr 2024 LLY

Popular weight-loss drug doesn't increase suicide risk, EU regulator says

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.

06:25 16 Apr 2024 LLY

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

04:30 16 Apr 2024 LLY

Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024

Healthcare's impact on the economy cannot be overstated. According to the American Medical Association, the U.S. spends more than $4 trillion a year on healthcare, which works out to nearly $13,000 per person.

03:55 16 Apr 2024 LLY

Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone

Reaching the trillion-dollar market cap is a testament to any company's international influence, massive customer base and brand power. Indeed, being considered a peer of global behemoths like Microsoft, Apple, Google, Meta and Nvidia is nothing to scoff at.

06:51 16 Apr 2024 LLY

Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know

Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.

09:27 16 Apr 2024 LLY

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

LLY Financial details

Company Rating
Strong Buy
Market Cap
714.63B
Income
5.24B
Revenue
34.12B
Book val./share
11.35
Cash/share
3.08
Dividend
4.69
Dividend %
0.62%
Employees
43K
Optionable
Yes
Shortable
Yes
Earnings
30 Apr 2024
P/E
136.17
Forward P/E
41.97
PEG
-76.48
P/S
20.94
P/B
66.25
P/C
243.65
P/FCF
-226.72
Quick Ratio
0.52
Current Ratio
0.94
Debt / Equity
2.34
LT Debt / Equity
1.69
-
-
EPS (TTM)
5.7
EPS next Y
17.88
EPS next Q
2.76
EPS this Y
-16.02%
EPS next Y
213.82%
EPS next 5Y
483.69%
EPS last 5Y
3.17%
Revenue last 5Y
8.86%
Revenue Q/Q
-1.53%
EPS Q/Q
-3720.69%
-
-
-
-
SMA20
0.26%
SMA50
16.87%
SMA100
27.64%
Inst Own
72.84%
Inst Trans
0.85%
ROA
8%
ROE
47%
ROC
0.19%
Gross Margin
80%
Oper. Margin
21%
Profit Margin
15%
Payout
78%
Shs Outstand
950.77M
Shs Float
849.82M
-
-
-
-
Target Price
421.78
52W Range
367.35-800.78
52W High
-6.19%
52W Low
+104.48%
RSI
46
Rel Volume
0.53
Avg Volume
3.08M
Volume
1.65M
Perf Week
-4.31%
Perf Month
-5.28%
Perf Quarter
30.14%
Perf Half Y
23.19%
-
-
-
-
Beta
0.367
-
-
Volatility
8.68%, 11.32%
Prev Close
-0.16%
Price
750.4448
Change
-1.2%

LLY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
23.9727.0431.2231.6537.91
Net income per share
4.986.826.156.935.82
Operating cash flow per share
5.197.168.017.864.71
Free cash flow per share
3.744.935.945.1-3.5
Cash per share
2.624.064.312.453.25
Book value per share
2.86.229.911.8111.97
Tangible book value per share
-8.16-5.94-2.68-0.56-1.09
Share holders equity per share
2.86.229.911.8111.97
Interest debt per share
17.418.6818.9918.3828.37
Market cap
122.37B153.24B250.52B329.89B524.73B
Enterprise value
135.84B166.18B263.59B344.06B547.14B
P/E ratio
26.3824.7444.8852.83100.13
Price to sales ratio
5.486.248.8511.5615.38
POCF ratio
25.323.5834.546.57123.75
PFCF ratio
35.1334.2846.571.71-166.48
P/B Ratio
46.9427.1627.930.9848.71
PTB ratio
46.9427.1627.930.9848.71
EV to sales
6.096.779.3112.0516.03
Enterprise value over EBITDA
20.5721.7530.1636.4743.93
EV to operating cash flow
28.0825.5736.348.57129.04
EV to free cash flow
3937.1748.9374.79-173.59
Earnings yield
0.040.040.020.020.01
Free cash flow yield
0.030.030.020.01-0.01
Debt to equity
6.062.941.881.522.34
Debt to assets
0.40.360.350.330.39
Net debt to EBITDA
2.041.691.51.51.8
Current ratio
1.161.41.231.050.94
Interest coverage
12.4216.8518.7121.4933.06
Income quality
0.581.051.31.130.81
Dividend Yield
0.020.020.010.010.01
Payout ratio
0.520.430.550.570.78
Sales general and administrative to revenue
0.280.250.230.230.2
Research and developement to revenue
0.250.250.250.250.27
Intangibles to total assets
0.260.240.240.230.19
Capex to operating cash flow
-0.28-0.31-0.26-0.35-1.74
Capex to revenue
-0.06-0.08-0.07-0.09-0.22
Capex to depreciation
-1.1-1.53-1.21-1.63-4.84
Stock based compensation to revenue
0.010.010.010.010.02
Graham number
17.7130.8937.0342.939.59
ROIC
0.230.230.220.240.23
Return on tangible assets
0.160.170.150.160.1
Graham Net
-30.5-32.99-30.55-30.97-43.13
Working capital
1.93B4.98B3.4B896.3M-1.57B
Tangible asset value
-7.6B-5.39B-2.43B-504.2M-982.6M
Net current asset value
-22.88B-23.35B-21.2B-20.68B-27.42B
Invested capital
6.062.941.881.522.34
Average receivables
5.66B6.24B7.53B8.34B9.95B
Average payables
1.31B1.51B1.64B1.8B2.26B
Average inventory
3.14B3.59B3.93B4.1B5.04B
Days sales outstanding
90.62103.06104.75109.45121.25
Days payables outstanding
108.64106.9583.38106.29144.25
Days of inventory on hand
246.68264.95193.96237.27320.42
Receivables turnover
4.033.543.483.333.01
Payables turnover
3.363.414.383.432.53
Inventory turnover
1.481.381.881.541.14
ROE
1.781.10.620.590.49
Capex per share
-1.45-2.24-2.07-2.75-8.21

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
7.687.729.2410.569.85
Net income per share
2.041.491.96-0.062.31
Operating cash flow per share
1.661.920.72.43-0.33
Free cash flow per share
1.080.92-0.23-2.01-2.07
Cash per share
2.334.073.142.773.08
Book value per share
11.2112.4212.312.4711.35
Tangible book value per share
-0.530.150.190.49-1.03
Share holders equity per share
11.2112.4212.312.4711.35
Interest debt per share
17.1821.0721.0522.5526.67
Market cap
347.61B309.42B421.94B483.31B553.41B
Enterprise value
361.79B324.76B438.07B501.1B575.82B
P/E ratio
44.8557.5259.83-2.11K63.18
Price to sales ratio
47.6144.4650.7650.8859.17
POCF ratio
220.05178.79667.73220.74-1.77K
PFCF ratio
339.43374.1-2.06K-266.77-281.92
P/B Ratio
32.6427.6538.1443.0751.38
PTB ratio
32.6427.6538.1443.0751.38
EV to sales
49.5546.6652.752.7561.56
Enterprise value over EBITDA
151.2190.59188.8378.29159.79
EV to operating cash flow
229.02187.66693.25228.86-1.85K
EV to free cash flow
353.27392.65-2.14K-276.59-293.34
Earnings yield
0.010000
Free cash flow yield
00000
Debt to equity
1.521.691.71.82.34
Debt to assets
0.330.360.340.350.39
Net debt to EBITDA
5.9296.952.786.22
Current ratio
1.051.31.131.050.94
Interest coverage
21.8614.5317.673.6132.85
Income quality
0.821.290.36-38.14-0.14
Dividend Yield
00000
Payout ratio
0.460.760.58-17.70.46
Sales general and administrative to revenue
0.230.250.230.190.16
Research and developement to revenue
0.270.290.280.250.27
Intangibles to total assets
0.230.210.20.190.19
Capex to operating cash flow
-0.35-0.52-1.32-1.835.29
Capex to revenue
-0.08-0.13-0.1-0.42-0.18
Capex to depreciation
-1.48-2.49-2.28-9.74-4.26
Stock based compensation to revenue
0.010.020.020.020.01
Graham number
22.6820.4223.294.2324.27
ROIC
0.060.040.0600.07
Return on tangible assets
0.050.030.0400.04
Graham Net
-29.39-32.36-35.08-37.66-40.9
Working capital
896.3M4.8B2.42B1.01B-1.57B
Tangible asset value
-504.2M134.7M166.9M440.5M-982.6M
Net current asset value
-20.68B-21.06B-22.33B-23.6B-27.42B
Invested capital
1.521.691.71.82.34
Average receivables
8.44B8.79B9.1B9.77B10.85B
Average payables
1.81B1.97B2.25B2.45B2.52B
Average inventory
4.07B4.43B4.67B4.85B5.34B
Days sales outstanding
105.49116.6799.398.2109.08
Days payables outstanding
112.24111.53123.2117.82140.98
Days of inventory on hand
250.55251.45238.95237.15313.17
Receivables turnover
0.850.770.910.920.83
Payables turnover
0.80.810.730.760.64
Inventory turnover
0.360.360.380.380.29
ROE
0.180.120.16-0.010.2
Capex per share
-0.58-1-0.93-4.45-1.74

LLY Frequently Asked Questions

What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY

Is Eli Lilly and Company buy or a sell ?

45 stock analysts have 45 predictions with a medium analyst target price of $383.89. The lowest prediction is $236 and the highest is $675

What is LLY stock prediction ?

With a median analyst target price of $535, 1 stock analysts have made 1 forecasts in last 90 days. $535 is the lowest and $535 is the greatest projection.

What is Eli Lilly and Company stock quote today ?

Eli Lilly and Company stock price is $750.4448 today.

Is Eli Lilly and Company stock public?

Yes, Eli Lilly and Company is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap